Levothyroxine Sodium

Product NDC: 70934-520
11-digit product format: 709340520
Labeler code: 70934
Product ID: 70934-520_a9532efb-a4bd-46c2-e053-2a95a90a3a8b
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: Levothyroxine Sodium
Dosage form: TABLET
Route: ORAL
Labeler: Denton Pharma, Inc. DBA Northwind Pharmaceuticals
Application: ANDA209713
Marketing category: ANDA
Marketing start: 2020-01-24
Marketing end: 0000-00-00
Substance: LEVOTHYROXINE SODIUM
Active strength: 0 mg/1
Pharmacologic classes: l-Thyroxine [EPC],Thyroxine [CS]
NDC exclude flag: No
Listing certified through: 2021-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 2 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Source date
excluded product	product	70934-520		D	Discontinued by firm		2026-10-05
excluded package	package	70934-520	70934-520-30	D	Discontinued by firm		2026-10-05

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 30 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Code	Status	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	70934-520-30	D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	70934-520-30	D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		D	Discontinued by firm	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	70934-520-30	D	Discontinued by firm	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		D	Discontinued by firm	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	70934-520-30	D	Discontinued by firm	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		D	Discontinued by firm	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	70934-520-30	D	Discontinued by firm	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		D	Discontinued by firm	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	70934-520-30	D	Discontinued by firm	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		D	Discontinued by firm	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	70934-520-30	D	Discontinued by firm	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		D	Discontinued by firm	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	70934-520-30	D	Discontinued by firm	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		D	Discontinued by firm	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	70934-520-30	D	Discontinued by firm	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		D	Discontinued by firm	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	70934-520-30	D	Discontinued by firm	`ad56d346431e…`	`cc804d4bbf1e…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded product	product		D	Discontinued by firm	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	70934-520-30	D	Discontinued by firm	`367a005e9d99…`	`383a685ebd0f…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded product	product		D	Discontinued by firm	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	70934-520-30	D	Discontinued by firm	`557ba5c1ecfa…`	`9c80585c8c6e…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded product	product		I	Inactivated by FDA	`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-08-30 03:57 UTC · source 2022-08-29	excluded package	package	70934-520-30	I	Inactivated by FDA	`fb8cb913e6d1…`	`eb8c232b6be0…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded product	product		I	Inactivated by FDA	`86f5da6cb304…`	`a595104c45d7…`
2022-04-09 23:13 UTC · source 2022-04-08	excluded package	package	70934-520-30	I	Inactivated by FDA	`86f5da6cb304…`	`a595104c45d7…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded product	product		I	Inactivated by FDA	`bd6a592717d7…`	`303034d00443…`
2022-04-04 05:40 UTC · source 2022-04-01	excluded package	package	70934-520-30	I	Inactivated by FDA	`bd6a592717d7…`	`303034d00443…`

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 12 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	Approval date
A209713-001	LEVOTHYROXINE SODIUM	LEVOTHYROXINE SODIUM	0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18
A209713-002	LEVOTHYROXINE SODIUM	LEVOTHYROXINE SODIUM	0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18
A209713-003	LEVOTHYROXINE SODIUM	LEVOTHYROXINE SODIUM	0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18
A209713-004	LEVOTHYROXINE SODIUM	LEVOTHYROXINE SODIUM	0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18
A209713-005	LEVOTHYROXINE SODIUM	LEVOTHYROXINE SODIUM	0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18
A209713-006	LEVOTHYROXINE SODIUM	LEVOTHYROXINE SODIUM	0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18
A209713-007	LEVOTHYROXINE SODIUM	LEVOTHYROXINE SODIUM	0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18
A209713-008	LEVOTHYROXINE SODIUM	LEVOTHYROXINE SODIUM	0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18
A209713-009	LEVOTHYROXINE SODIUM	LEVOTHYROXINE SODIUM	0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18
A209713-010	LEVOTHYROXINE SODIUM	LEVOTHYROXINE SODIUM	0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18
A209713-011	LEVOTHYROXINE SODIUM	LEVOTHYROXINE SODIUM	0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18
A209713-012	LEVOTHYROXINE SODIUM	LEVOTHYROXINE SODIUM	0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 36 matching rows.

Application-product, TE code table
Application-product	TE code
A209713-001	AB1
A209713-001	AB2
A209713-001	AB3
A209713-002	AB1
A209713-002	AB2
A209713-002	AB3
A209713-003	AB1
A209713-003	AB2
A209713-003	AB3
A209713-004	AB1
A209713-004	AB2
A209713-004	AB3
A209713-005	AB1
A209713-005	AB2
A209713-005	AB3
A209713-006	AB1
A209713-006	AB2
A209713-006	AB3
A209713-007	AB1
A209713-007	AB2
A209713-007	AB3
A209713-008	AB1
A209713-008	AB2
A209713-008	AB3
A209713-009	AB1
A209713-009	AB2
A209713-009	AB3
A209713-010	AB1
A209713-010	AB2
A209713-010	AB3
A209713-011	AB1
A209713-011	AB2
A209713-011	AB3
A209713-012	AB1
A209713-012	AB2
A209713-012	AB3

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 13 · 516 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	Product TE source text	Approval date	Source SHA-256
2026-09-14 22:38:34	2026-08	A209713-001	LEVOTHYROXINE SODIUM	0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-002	LEVOTHYROXINE SODIUM	0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-003	LEVOTHYROXINE SODIUM	0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-004	LEVOTHYROXINE SODIUM	0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-005	LEVOTHYROXINE SODIUM	0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-006	LEVOTHYROXINE SODIUM	0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-007	LEVOTHYROXINE SODIUM	0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-008	LEVOTHYROXINE SODIUM	0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-009	LEVOTHYROXINE SODIUM	0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-010	LEVOTHYROXINE SODIUM	0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-011	LEVOTHYROXINE SODIUM	0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-012	LEVOTHYROXINE SODIUM	0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	A209713-001	LEVOTHYROXINE SODIUM	0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A209713-002	LEVOTHYROXINE SODIUM	0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A209713-003	LEVOTHYROXINE SODIUM	0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A209713-004	LEVOTHYROXINE SODIUM	0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A209713-005	LEVOTHYROXINE SODIUM	0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A209713-006	LEVOTHYROXINE SODIUM	0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A209713-007	LEVOTHYROXINE SODIUM	0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A209713-008	LEVOTHYROXINE SODIUM	0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A209713-009	LEVOTHYROXINE SODIUM	0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A209713-010	LEVOTHYROXINE SODIUM	0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A209713-011	LEVOTHYROXINE SODIUM	0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A209713-012	LEVOTHYROXINE SODIUM	0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	A209713-001	LEVOTHYROXINE SODIUM	0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A209713-002	LEVOTHYROXINE SODIUM	0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A209713-003	LEVOTHYROXINE SODIUM	0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A209713-004	LEVOTHYROXINE SODIUM	0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A209713-005	LEVOTHYROXINE SODIUM	0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A209713-006	LEVOTHYROXINE SODIUM	0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A209713-007	LEVOTHYROXINE SODIUM	0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A209713-008	LEVOTHYROXINE SODIUM	0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A209713-009	LEVOTHYROXINE SODIUM	0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A209713-010	LEVOTHYROXINE SODIUM	0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A209713-011	LEVOTHYROXINE SODIUM	0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A209713-012	LEVOTHYROXINE SODIUM	0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A209713-001	LEVOTHYROXINE SODIUM	0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A209713-002	LEVOTHYROXINE SODIUM	0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A209713-003	LEVOTHYROXINE SODIUM	0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A209713-004	LEVOTHYROXINE SODIUM	0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium	TABLET / ORAL	AB1,AB2,AB3	2019-01-18	`31067a03dcf5…`

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 38 · 1,500 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	TE code	Order	Source SHA-256
2026-09-14 22:38:34	2026-08	A209713-001	AB1	1	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-001	AB2	2	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-001	AB3	3	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-002	AB1	1	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-002	AB2	2	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-002	AB3	3	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-003	AB1	1	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-003	AB2	2	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-003	AB3	3	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-004	AB1	1	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-004	AB2	2	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-004	AB3	3	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-005	AB1	1	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-005	AB2	2	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-005	AB3	3	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-006	AB1	1	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-006	AB2	2	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-006	AB3	3	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-007	AB1	1	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-007	AB2	2	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-007	AB3	3	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-008	AB1	1	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-008	AB2	2	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-008	AB3	3	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-009	AB1	1	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-009	AB2	2	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-009	AB3	3	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-010	AB1	1	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-010	AB2	2	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-010	AB3	3	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-011	AB1	1	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-011	AB2	2	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-011	AB3	3	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-012	AB1	1	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-012	AB2	2	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	A209713-012	AB3	3	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	A209713-001	AB1	1	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A209713-001	AB2	2	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A209713-001	AB3	3	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	A209713-002	AB1	1	`caaa826d4ba7…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
70934-520-30	2023-02-13	C162847	48780-1	d6a99b39-7c32-a426-e053-dadaa90af4c2	These highlights do not include all the information needed to use levothyroxine sodium tablets safely and effectively. See full prescribing information for levothyroxine sodium tablets. LEVOTHYROXINE SODIUM tablets, for oral use Initial U.S. Approval: 2002
70934-520-30	2022-01-28	C162847	48780-1	d6a99b39-7c32-a426-e053-dadaa90af4c2	These highlights do not include all the information needed to use levothyroxine sodium tablets safely and effectively. See full prescribing information for levothyroxine sodium tablets. LEVOTHYROXINE SODIUM tablets, for oral use Initial U.S. Approval: 2002

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
70934-520-30	EA - Each	70934-520	6c1142db-9bc3-49f1-a75a-0587355179fe	1	2022-12-07

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 2 of 4 · 62 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	A-S Medication Solutions	4f26f9dc-cf49-4b55-a6f7-f2f579893ee4	2026-02-10	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	Northwind Health Company, LLC	ffc34bc6-5de5-addb-e053-6294a90a25be	2026-01-26	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	NuCare Pharmaceuticals, Inc.	49136b34-1bc1-ec4e-e063-6394a90ac9dd	2026-01-23	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	A-S Medication Solutions	e2291336-1188-48f4-af52-d12ac892f80f	2026-01-14	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	A-S Medication Solutions	98d7ce2b-a248-4ed0-a2ec-d28ba623531e	2026-01-14	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	Northwind Health Company, LLC	d9cb3417-e8cb-13f8-e053-2a95a90a294b	2026-01-01	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	Northwind Health Company, LLC	ca4634a5-d8d7-48a4-e053-2995a90a0cd4	2026-01-01	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	Northwind Health Company, LLC	dac0af5d-622c-e18c-e053-2995a90a5739	2026-01-01	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	Northwind Health Company, LLC	f317a597-4644-746a-e053-2995a90a807f	2026-01-01	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	Northwind Health Company, LLC	e0503b8c-7eb7-269e-e053-2995a90a1bca	2026-01-01	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	Northwind Health Company, LLC	e08c2af4-c20a-3176-e053-2a95a90a1aa9	2026-01-01	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	Northwind Health Company, LLC	e3d949ce-731b-6dfe-e053-2a95a90a0074	2026-01-01	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	Northwind Health Company, LLC	d9dfd5b8-06a5-2728-e053-2995a90a298e	2026-01-01	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	Northwind Health Company, LLC	d9dff641-ced3-bae3-e053-2a95a90a2e29	2026-01-01	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	A-S Medication Solutions	e3667ab1-2bd9-4e0d-8a97-f907593e7954	2025-12-16	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	A-S Medication Solutions	eb120047-a43b-40a4-9f55-067b1b51edda	2025-12-16	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	A-S Medication Solutions	fea284d8-0514-498b-a37c-405730b5f6a2	2025-11-18	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	Proficient Rx LP	bcf10012-8920-4737-92f5-7401ee0c5894	2025-10-01	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	Preferred Pharmaceuticals Inc.	884f9fa1-58aa-4ff7-934f-106a0470e747	2025-07-03	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713
Levothyroxine Sodium	LEVOTHYROXINE SODIUM	Major Pharmaceuticals	333642fd-93ae-4dc0-9c83-6d6b163c1c74	2025-06-19	Boxed warning, Warnings, Adverse reactions	Exact identifier application applno (ANDA): 209713 application number: ANDA209713

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
9J765S329G	LEVOTHYROXINE SODIUM	6106-07-6	LEVOTHYROXINE SODIUM

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Units	Marketing start	Marketing end	Sample	Exclude flag	Status
70934-520-30	70934052030	30 TABLET in 1 BOTTLE, PLASTIC (70934-520-30)	30 tablet	2020-01-24	0000-00-00	No	No	Current

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
Levothyroxine Sodium	Denton Pharma, Inc. DBA Northwind Pharmaceuticals	2020-01-24	HUMAN PRESCRIPTION DRUG LABEL	1